Cargando…

Monocaprin Enhances Bioavailability of Fucoxanthin in Diabetic/Obese KK-A(y) Mice

Fucoxanthin is a marine carotenoid found in brown seaweeds and several microalgae. It has been reported that fucoxanthin has health benefits such as anti-obesity and anti-diabetic effects. To facilitate fucoxanthin applications in the food industry, it is important to improve its low bioavailability...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagata, Kodai, Takatani, Naoki, Beppu, Fumiaki, Abe, Aya, Tominaga, Etsuko, Fukuhara, Tomohisa, Ozeki, Makoto, Hosokawa, Masashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9325202/
https://www.ncbi.nlm.nih.gov/pubmed/35877739
http://dx.doi.org/10.3390/md20070446
_version_ 1784756991150784512
author Nagata, Kodai
Takatani, Naoki
Beppu, Fumiaki
Abe, Aya
Tominaga, Etsuko
Fukuhara, Tomohisa
Ozeki, Makoto
Hosokawa, Masashi
author_facet Nagata, Kodai
Takatani, Naoki
Beppu, Fumiaki
Abe, Aya
Tominaga, Etsuko
Fukuhara, Tomohisa
Ozeki, Makoto
Hosokawa, Masashi
author_sort Nagata, Kodai
collection PubMed
description Fucoxanthin is a marine carotenoid found in brown seaweeds and several microalgae. It has been reported that fucoxanthin has health benefits such as anti-obesity and anti-diabetic effects. To facilitate fucoxanthin applications in the food industry, it is important to improve its low bioavailability. We attempted the combined feeding of fucoxanthin-containing seaweed oil (SO) and monocaprin in a powder diet and analyzed the fucoxanthin metabolite contents in the liver, small intestine and serum of diabetic/obese KK-A(y) mice. After 4 weeks of feeding with the experimental diets, the serum fucoxanthinol concentrations of the mice fed 0.2% SO and 0.5% monocaprin were higher than those of the 0.2% SO-fed mice. Furthermore, fucoxanthinol accumulation in the liver and small intestine tended to increase in a combination diet of 0.2% SO and 0.125–0.5% monocaprin compared with a diet of 0.2% SO alone, although amarouciaxanthin A accumulation was not different among the 0.2% SO-fed groups. These results suggest that a combination of monocaprin with fucoxanthin-containing SO is an effective treatment for improving the bioavailability of fucoxanthin.
format Online
Article
Text
id pubmed-9325202
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93252022022-07-27 Monocaprin Enhances Bioavailability of Fucoxanthin in Diabetic/Obese KK-A(y) Mice Nagata, Kodai Takatani, Naoki Beppu, Fumiaki Abe, Aya Tominaga, Etsuko Fukuhara, Tomohisa Ozeki, Makoto Hosokawa, Masashi Mar Drugs Communication Fucoxanthin is a marine carotenoid found in brown seaweeds and several microalgae. It has been reported that fucoxanthin has health benefits such as anti-obesity and anti-diabetic effects. To facilitate fucoxanthin applications in the food industry, it is important to improve its low bioavailability. We attempted the combined feeding of fucoxanthin-containing seaweed oil (SO) and monocaprin in a powder diet and analyzed the fucoxanthin metabolite contents in the liver, small intestine and serum of diabetic/obese KK-A(y) mice. After 4 weeks of feeding with the experimental diets, the serum fucoxanthinol concentrations of the mice fed 0.2% SO and 0.5% monocaprin were higher than those of the 0.2% SO-fed mice. Furthermore, fucoxanthinol accumulation in the liver and small intestine tended to increase in a combination diet of 0.2% SO and 0.125–0.5% monocaprin compared with a diet of 0.2% SO alone, although amarouciaxanthin A accumulation was not different among the 0.2% SO-fed groups. These results suggest that a combination of monocaprin with fucoxanthin-containing SO is an effective treatment for improving the bioavailability of fucoxanthin. MDPI 2022-07-07 /pmc/articles/PMC9325202/ /pubmed/35877739 http://dx.doi.org/10.3390/md20070446 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Nagata, Kodai
Takatani, Naoki
Beppu, Fumiaki
Abe, Aya
Tominaga, Etsuko
Fukuhara, Tomohisa
Ozeki, Makoto
Hosokawa, Masashi
Monocaprin Enhances Bioavailability of Fucoxanthin in Diabetic/Obese KK-A(y) Mice
title Monocaprin Enhances Bioavailability of Fucoxanthin in Diabetic/Obese KK-A(y) Mice
title_full Monocaprin Enhances Bioavailability of Fucoxanthin in Diabetic/Obese KK-A(y) Mice
title_fullStr Monocaprin Enhances Bioavailability of Fucoxanthin in Diabetic/Obese KK-A(y) Mice
title_full_unstemmed Monocaprin Enhances Bioavailability of Fucoxanthin in Diabetic/Obese KK-A(y) Mice
title_short Monocaprin Enhances Bioavailability of Fucoxanthin in Diabetic/Obese KK-A(y) Mice
title_sort monocaprin enhances bioavailability of fucoxanthin in diabetic/obese kk-a(y) mice
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9325202/
https://www.ncbi.nlm.nih.gov/pubmed/35877739
http://dx.doi.org/10.3390/md20070446
work_keys_str_mv AT nagatakodai monocaprinenhancesbioavailabilityoffucoxanthinindiabeticobesekkaymice
AT takataninaoki monocaprinenhancesbioavailabilityoffucoxanthinindiabeticobesekkaymice
AT beppufumiaki monocaprinenhancesbioavailabilityoffucoxanthinindiabeticobesekkaymice
AT abeaya monocaprinenhancesbioavailabilityoffucoxanthinindiabeticobesekkaymice
AT tominagaetsuko monocaprinenhancesbioavailabilityoffucoxanthinindiabeticobesekkaymice
AT fukuharatomohisa monocaprinenhancesbioavailabilityoffucoxanthinindiabeticobesekkaymice
AT ozekimakoto monocaprinenhancesbioavailabilityoffucoxanthinindiabeticobesekkaymice
AT hosokawamasashi monocaprinenhancesbioavailabilityoffucoxanthinindiabeticobesekkaymice